Viridian Therapeutics, Inc. (VRDN) Tops Q1 EPS by 11c

Viridian Therapeutics, Inc. (NASDAQ: VRDN) reported Q1 EPS of ($0.87), $0.11 better than the analyst estimate of ($0.98). Revenue for the quarter came in at $70 thousand versus the consensus estimate of $52.09 thousand.

For earnings history and earnings-related data on Viridian Therapeutics, Inc. (VRDN) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Bernstein SocGen on Performance Food Group (PFGC): 'Not the quarter we were hoping for, but LT story intact'
• SuperCom (SPCB) Tops Q3 EPS by 43c